Science News Round Up, April 2, 2025

by Jon Scaccia April 2, 2025

Be a Science Advocate—Support Independent Knowledge!

Stay informed with the latest research advancements and scientific breakthroughs. Your free subscription directly supports our self-funded mission to deliver crucial updates weekly. 💡 Every moment counts! Share now and invite others to amplify this important message!

Introducing the Stars of Blue Origin’s All-Female Flight

Blue Origin’s NS-31 mission is set to make history with its first all-female crew featuring prominent figures like Katy Perry, Lauren Sánchez, and Gayle King, representing a significant step towards greater gender and ethnic diversity in space exploration. The mission, coinciding with Women’s History Month, aims to inspire future generations by challenging stereotypes and showcasing that space exploration is accessible to diverse backgrounds, as it pushes the boundaries of what’s possible for women in traditionally male-dominated fields.

Uncertainty of 21st Century western U.S. snowfall loss derived from regional climate model large ensemble

The western United States faces a significant threat to its water resources as climate models predict that most winter snowfall over its mountains could turn to rain by the end of the century, leading to a potential loss of up to 34% of snowfall under high-emission scenarios. (this is an important plot point in the movie Chinatown) This change could drastically affect water availability for nearly 100 million people and elevate flood and fire risks, emphasizing the urgent need for mitigation efforts to curb emissions and adapt water management strategies to secure future water supply.

Immune checkpoints regulate acute myeloid leukemia stem cells

Acute myeloid leukemia stem cells (LSCs) exhibit a unique combination of expressing immune checkpoint molecules like those found in antigen-presenting cells, contributing to their ability to evade the immune system and resist chemotherapy. While current immune checkpoint inhibitors show limited efficacy in LSCs, targeting LSC-specific immune checkpoints could offer new therapeutic avenues, potentially overcoming the challenges of relapse and treatment resistance in AML